https://doi.org/10.4081/reumatismo.2025.1756
Antisynthetase syndrome with anti-glycyl tRNA synthetase antibodies in a patient with axial spondyloarthritis treated with tumor necrosis factor-α inhibitors
Submitted: 17 June 2024
Accepted: 15 August 2024
Published: 10 February 2025
Accepted: 15 August 2024
Abstract Views: 130
PDF: 56
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
We present a case of interstitial lung disease arising in the course of antisynthetase syndrome (ASSD) in a patient with axial spondyloarthritis (ax-SpA) undergoing tumor necrosis factor-α (TNF-α) inhibitors therapy. Only two cases of ASSD in ax-SpA patients have been described in the literature, although with a different autoantibody profile. Only in one case, ASSD manifested with lung involvement, without the possible implication of TNF-α inhibitors in the pathogenesis, as it occurred concurrently with spondyloarthritis. Our case is the first to emphasize the coexistence of ASSD with anti-glycyl tRNA synthetase antibodies and ax-SpA, reminding us of the possible, although rare, adverse effects on the lungs with TNF-α inhibitors.
Sawal N, Mukhopadhyay S, Rayancha S, Moore A, Garcha P, Kumar A, et al. A narrative review of interstitial lung disease in antisynthetase syndrome: a clinical approach. J Thorac Dis 2021; 13: 5556-71.
DOI: https://doi.org/10.21037/jtd-20-3328
Oldroyd AGS, Lilleker JB, Amin T, Aragon O, Bechman K, Cuthbert V, et al. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology 2022; 61: 1760-8.
DOI: https://doi.org/10.1093/rheumatology/keac115
Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68: 777-83.
DOI: https://doi.org/10.1136/ard.2009.108233
Zanframundo G, Faghihi-Kashani S, Scirè CA, Bonella F, Corte TJ, Doyle TJ, et al. Defining anti-synthetase syndrome: a systematic literature review. Clin Exp Rheumatol 2022; 40: 309-19.
DOI: https://doi.org/10.55563/clinexprheumatol/8xj0b9
Katzap E, Barilla-LaBarca ML, Marder G. Antisynthetase syndrome. Curr Rheumatol Rep 2011; 13: 175-81.
DOI: https://doi.org/10.1007/s11926-011-0176-8
Chawla A, Kumar T, Mukherjee P. Antisynthetase syndrome: Initial and follow-up imaging features. Lung India 2018; 35: 523-5.
DOI: https://doi.org/10.4103/lungindia.lungindia_4_18
Meyer O, Charlanne H, Cherin P, Allanore Y, Coquerelle P, Grardel B, et al. Subluxing arthropathy: an unusual manifestation of the antisynthetase syndrome. Ann Rheum Dis 2009; 68: 152-3.
DOI: https://doi.org/10.1136/ard.2007.078907
Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 2014; 73: 227-32.
DOI: https://doi.org/10.1136/annrheumdis-2012-201800
Cavagna L, Trallero-Araguás E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E, et al. Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course. J Clin Med 2019; 8: 2013.
DOI: https://doi.org/10.3390/jcm8112013
Bozzalla-Cassione E, Zanframundo G, Biglia A, Bellis E, Bozzini S, Codullo V, et al. Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single centre cohort study. Clin Exp Rheumatol 2022; 40: 27-31.
DOI: https://doi.org/10.55563/clinexprheumatol/bjb2gf
Ge Y, He L. Coexistence of axial spondyloarthritis and idiopathic inflammatory myopathy. Case Rep Rheumatol 2020; 2020:8840642.
DOI: https://doi.org/10.1155/2020/8840642
Nouijai A, Ghazi M, Mounach A, Achemlal L, Bezza A, El Maghraoui A. Antisynthetase syndrome in a patient with ankylosing spondylitis. Joint Bone Spine 2007; 74: 511-2.
DOI: https://doi.org/10.1016/j.jbspin.2007.01.028
Chen HH, Chao WC, Chen YH, Hsieh TY, Lai KL, Chen YM, et al. Risk of immunemediated inflammatory diseases in newly diagnosed ankylosing spondylitis patients: a population-based matched cohort study. Arthritis Res Ther 2019; 21: 196.
DOI: https://doi.org/10.1186/s13075-019-1980-1
Brunasso AM, Aberer W, Massone C. New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review. ScientificWorldJournal 2014; 2014: 179180.
DOI: https://doi.org/10.1155/2014/179180
Koo BS, Hong S, Kim YJ, Kim YG, Lee CK, Yoo B. Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent. Korean J Intern Med 2015; 30: 104-9.
DOI: https://doi.org/10.3904/kjim.2015.30.1.104
How to Cite
Iacovantuono, M., Bonini, C., Di Biase, E., Magliacani, V., & Sebastiani, G. D. (2025). Antisynthetase syndrome with anti-glycyl tRNA synthetase antibodies in a patient with axial spondyloarthritis treated with tumor necrosis factor-α inhibitors. Reumatismo. https://doi.org/10.4081/reumatismo.2025.1756
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- S. Scriffignano, F.M. Perrotta, M. Ricci, B. Carabellese, E. Lubrano , Visceral muscle dysmotility syndrome in systemic lupus erythematosus: which is the role of 18 fluorodeoxyglucose-positron emission tomography-computed tomography? A clinical case and literature review , Reumatismo: Vol. 76 No. 4 (2024)
- A. Alunno, O. Bistoni, E. Bartoloni Bocci, S. Caterbi, B. Bigerna, A. Pucciarini, A. Tabarrini, R. Mannucci, D. Beghelli, B. Falini, R. Gerli, IL-17-producing double-negative T cells are expanded in the peripheral blood, infiltrate the salivary gland and are partially resistant to corticosteroid therapy in patients with Sjögren’s syndrome , Reumatismo: Vol. 65 No. 4 (2013)
- M. Polastri, L. Di Marco, S. Cantagalli, M. Di Eusanio, Octogenarian with an untreated femoral neck fracture: upright position during the postoperative course after aortic valve replacement , Reumatismo: Vol. 67 No. 1 (2015)
- B. Gatto, Biologics targeted at TNF: design, production and challenges , Reumatismo: Vol. 58 No. 2 (2006)
- D. Biscontini, E. Bartoloni Bocci, R. Gerli, Analysis of foot structural damage in rheumatoid arthritis: clinical evaluation by validated measures and serological correlations , Reumatismo: Vol. 61 No. 1 (2009)
- E. Catarsi, M. Doveri, A. Tavoni, Bosentan and sildenafil: successful treatment in a sclerodermic patient with refractory ulcers , Reumatismo: Vol. 65 No. 2 (2013)
- K. Stefanantoni, I. Sciarra, M. Vasile, R. Badagliacca, R. Poscia, M. Pendolino, C. Alessandri, C.D. Vizza, G. Valesini, V. Riccieri, Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor β in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension , Reumatismo: Vol. 66 No. 4 (2014)
- A. Lo Gullo, G. Mandraffino, C.O. Aragona, A. Molica Colella, A. Saitta, E. Imbalzano, Subcutaneous administration of tocilizumab is effective in myointimal hyperplasia remodelling in refractory Takayasu arteritis , Reumatismo: Vol. 69 No. 4 (2017)
- A. Corrado, F.P. Cantatore, Dupuytren’s disease. State of the art and therapeutic perspectives , Reumatismo: Vol. 59 No. 2 (2007)
- M. Colaci, D. Giuggioli, A. Manfredi, M. Sebastiani, F. Coppi, R. Rossi, C. Ferri, Aortic pulse wave velocity measurement in systemic sclerosis patients , Reumatismo: Vol. 64 No. 6 (2012)
<< < 16 17 18 19 20 21 22 23 24 25 > >>
You may also start an advanced similarity search for this article.
